» Authors » Daniela Zob

Daniela Zob

Explore the profile of Daniela Zob including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 6
Citations 25
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
1.
Tsoulos N, Agiannitopoulos K, Potska K, Katseli A, Ntogka C, Pepe G, et al.
Cancer Genomics Proteomics . 2024 Aug; 21(5):448-463. PMID: 39191493
Background/aim: The application of next-generation sequencing (NGS) technology in the genetic investigation of hereditary cancer is important for clinical surveillance, therapeutic approach, and reducing the risk of developing new malignancies....
2.
Simion L, Ionescu S, Chitoran E, Rotaru V, Cirimbei C, Madge O, et al.
Medicina (Kaunas) . 2023 Sep; 59(9). PMID: 37763651
: Due to its many benefits, indocyanine green (ICG) has gained progressive popularity in operating rooms (ORs) globally. This literature review examines its qualitative and quantitative usage in surgical treatment....
3.
Volovat S, Augustin I, Zob D, Boboc D, Amurariti F, Volovat C, et al.
Cancers (Basel) . 2022 Oct; 14(19). PMID: 36230757
Colorectal cancer is a major cause of cancer-related death worldwide and is correlated with genetic and epigenetic alterations in the colonic epithelium. Genetic changes play a major role in the...
4.
Vrabie E, Alecu M, Cirimbei C, Daha C, Prunoiu V, Stanculeanu D, et al.
Chirurgia (Bucur) . 2021 May; 116(2):186-192. PMID: 33950814
We are presenting the experience of our centre with the surgical treatment of breast cancer, by comparing the use of axillary node dissection with sentinel lymph node biopsy (SNLB). We...
5.
Jinga D, Ciuleanu T, Negru S, Aldea C, Gales L, Bacanu F, et al.
J BUON . 2017 Nov; 22(5):1287-1295. PMID: 29135115
Purpose: The Romanian Patient Access Program (Ro-PAP, CA 184-427), part of the European Expanded Access Program (EAP), was developed to evaluate the effectiveness and safety profile ipilimumab in previously treated...
6.
Stanculeanu D, Zob D, Toma O, Georgescu B, Papagheorghe L, Mihaila R
Maedica (Bucur) . 2017 Sep; 12(1):48-54. PMID: 28878837
Antineoplastic targeted therapies, such as EGFR inhibitors, tyrosine kinase inhibitors and BRAF inhibitors, frequently lead to systemic and cutaneous side effects, significantly affecting patient's quality of life. Patients with new...